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Abstract: Rituximab is a human/murine, chi-
meric anti-CD20 monoclonal antibody with
established efficacy, and a favorable and
well-defined safety profile in patients with var-
ious CD20-expressing lymphoid malignancies,
including indolent and aggressive forms of
B-cell non-Hodgkin lymphoma. Since its first
approval 20 years ago, intravenously adminis-
tered rituximab has revolutionized the
treatment of B-cell malignancies and has
become a standard component of care for fol-
licular lymphoma, diffuse large B-cell lym-
phoma, chronic lymphocytic leukemia, and
mantle cell lymphoma. For all of these diseases,
clinical trials have demonstrated that rituximab
not only prolongs the time to disease progres-
sion but also extends overall survival. Efficacy
benefits have also been shown in patients with
marginal zone lymphoma and in more aggres-
sive diseases such as Burkitt lymphoma.
Although the proven clinical efficacy and suc-
cess of rituximab has led to the development of
other anti-CD20 monoclonal antibodies in
recent years (e.g., obinutuzumab, ofatumumab,
veltuzumab, and ocrelizumab), rituximab is
likely to maintain a position within the thera-
peutic armamentarium because it is well estab-
lished with a long history of successful clinical
use. Furthermore, a subcutaneous formulation
of the drug has been approved both in the EU
and in the USA for the treatment of B-cell
malignancies. Using the wealth of data pub-
lished on rituximab during the last two decades,
we review the preclinical development of
rituximab and the clinical experience gained in
the treatment of hematologic B-cell malignan-
cies, with a focus on the well-established intra-
venous route of administration. This article is a
companion paper to A. Davies, et al., which is
also published in this issue.
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INTRODUCTION
Hematologic B-cell malignancies comprise a
large, heterogeneous group of lymphoprolifer-
ative disorders that range from slow-growing,
indolent non-Hodgkin lymphomas (NHLs),
such as follicular lymphoma (FL) and chronic
lymphocytic leukemia (CLL), to more aggressive
forms of NHL, such as diffuse large B-cell lym-
phoma (DLBCL) [1, 2]. B-cell disorders represent
more than 85% of all NHL cases [3]. In 2012,
there were an estimated 385,700 new cases of
NHL worldwide, with an estimated 199,700
patients dying from the disease [4], and evi-
dence from US and UK statistics suggests that
the annual incidence has been rising steadily
since the 1970s [5, 6]. NHL incidence rates are
higher among the elderly population than in
the younger population, with diagnoses of NHL
most common among patients aged 65–74 years
[7], and a projection of population dynamics for
CLL patients in the USA predicts that 199,000
patients will have the disease in 2025, partly
driven by improved survival [8]. In view of the
aging population worldwide, the diagnosis and
treatment of B-cell hematologic malignancies
are likely to remain an important focus for
healthcare providers for the foreseeable future.
The treatment strategy for NHL is largely
determined by histologic features, disease stage,
patient age, prognosis, and the presence of
comorbid disease. Staging is established using
validated systems, which include the Ann Arbor
staging classification for DLBCL [9] and FL [10],
and the Binet and Rai staging systems for CLL
[11]. Prognostic assessments at initial diagnosis
are based on the International Prognostic Index
(IPI) and age-adjusted IPI for DLBCL [9], the
Follicular Lymphoma International Prognostic
Index for FL [10], and the Mantle Cell Lym-
phoma International Prognostic Index for
mantle cell lymphoma (MCL) [12]. In CLL, the
Binet and Rai staging systems are both used to
categorize patients into three groups according
to their prognosis [11], and the International
Prognostic Index for patients with CLL may also
be applied [13]. In DLBCL, gene expression
profiling can now be used to determine prog-
nosis by identifying distinct disease subtypes
according to their cell of origin [14, 15].
The development of monoclonal antibodies
(mAbs) as a therapeutic treatment began in
1975 by researchers funded by the National
Cancer Institute, Ce´sar Milstein and Georges
Ko¨hler [16], who described the formation of
hybridomas to rescue and produce a limitless
supply of mAbs from a single B cell. For this
work, Milstein and Ko¨hler received the Nobel
Prize for Physiology or Medicine in 1984 jointly
with Niels Jerne [17]. Treatment with the first
mAb occurred in 1980 [18], and this was fol-
lowed by pioneering studies by Ron Levy’s
group at Stanford University, which produced
patient-specific monoclonal anti-idiotype anti-
bodies for treating lymphoma patients [19].
These studies proved the concept that mAbs
could have a dramatic antitumor effect and that
they were safe, but commercialization was lim-
ited by the fact they were patient specific. At the
same time, antibodies were being used to
investigate cell-surface proteins, resulting in the
identification of B-cell-restricted antigens such
as CD19 and CD20. This discovery paved the
way for the production of therapeutic mAbs
that could be used in patients whose tumors
expressed those antigens. Given the widespread
expression of CD20 on malignant B cells,
treatment with a murine mAb against CD20 was
undertaken [20], and demonstrated safety,
albeit with limited clinical activity. This ulti-
mately led to the development of a chimeric
anti-CD20 mAb with increased antitumor
activity; namely, rituximab.
Rituximab (MabThera/Rituxan/Rituxan
HYCELATM, F. Hoffmann-La Roche Ltd.) is a
human/murine chimeric, glycosylated
immunoglobulin (Ig) G1-j mAb containing
murine light- and heavy-chain variable region
sequences, and human kappa and human IgG1
constant region sequences. Rituximab has
specific affinity for the B-lymphocyte trans-
membrane protein, CD20, which is expressed
on normal B cells (excluding stem cells, pro-B
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cells, and plasma B cells) and on most malig-
nant B cells [21].
Intravenously administered rituximab was
granted regulatory approval in 1997 by the US
Food and Drug Administration and in 1998 by
the European Medicines Agency for use in
relapsed/refractory indolent NHL. Approvals for
use in CLL followed in 2009 and 2010, respec-
tively. Intravenously administered rituximab
was the first therapeutic mAb to be used in the
field of oncology, establishing a new class of
anticancer drugs. Since its approval, rituximab
has revolutionized the treatment of B-cell
malignancies, becoming a standard component
of care for FL [10, 22], DLBCL [9, 22], and CLL
[11, 23]. Rituximab has also been included in
the WHO Model List of Essential Medicines
since 2015 [24]. A new formulation of rituximab
for subcutaneous administration has also been
approved in the EU and USA for the treatment
of patients with NHL and CLL, based primarily
on the results of the SABRINA and SAWYER
clinical trials [25, 26]. Subcutaneously admin-
istered rituximab was developed primarily to
simplify administration and shorten the
administration time, and thus improve the
patient experience by decreasing the burden of
treatment. In addition, this may facilitate access
to this important drug in resource-poor settings
where intravenous administration may pose a
particular challenge.
Clinical experience with intravenously
administered rituximab in B-cell hematologic
malignancies is extensive, currently extending
to 20 years and to more than four million
patient exposures worldwide, including data
from an estimated 18,000 patients treated with
rituximab in corporate-sponsored or supported
clinical trials (Roche, data on file not publically
available). Clinical experience with rituximab
also extends to off-label use in MCL, for which
rituximab is a standard component of care [27],
and in other hematologic malignancies,
including marginal zone lymphoma, Hodgkin
lymphoma, Burkitt lymphoma, and B-lineage
acute lymphoblastic leukemia (see ‘‘Clinical
Efficacy of Rituximab’’), as well as to non-
hematologic licensed indications, including
rheumatoid arthritis, and granulomatosis with
polyangiitis and microscopic polyangiitis
[28–30], which are outside the scope of this
review.
This article reviews the preclinical devel-
opment of rituximab and clinical experience
with the intravenous formulation in B-cell
hematologic malignancies. Discussion of the
preclinical and clinical experience with sub-
cutaneously administered rituximab is outside
the scope of this review, but is covered
extensively in a recent publication by Davies
et al. [31].The information reported in this
article is derived from previously conducted
studies, and does not include any new studies
of human or animal subjects performed by
any of the authors.
MECHANISM OF ACTION
OF RITUXIMAB
Rituximab binds with high affinity and speci-
ficity to the CD20 antigen, which is expressed
on the vast majority of malignant B cells. The
apparent affinity constant of rituximab for
human CD20, as determined by Scatchard
analysis using a human lymphoblastoid cell line
(SB), is approximately 5.2 nmol/L [32]. The
characteristics of rituximab binding to the
CD20 molecule led to the definition of the
‘‘type I’’ anti-CD20 mAbs, which share several
properties and are distinct from type II mAbs
such as obinutuzumab. At least four mechanis-
tic pathways are thought to be responsible for
the elimination of CD20? cells by rituximab
(Fig. 1): antibody-dependent cellular cytotoxic-
ity (ADCC), antibody-dependent cellular
phagocytosis, complement-dependent cytotox-
icity (CDC), and direct antitumor effects via
either apoptosis or other cell death pathways
[33–36]. Binding of the fragment crystallizable
(Fc) portion of the rituximab mAb to tumor
cells results in the reorganization of CD20
molecules into lipid rafts and subsequent acti-
vation of the classical pathway of the comple-
ment cascade. This leads to CDC, including
tumor cell lysis and augmentation of phagocy-
tosis. ADCC occurs as a result of an interaction
between the Fc portion of rituximab in anti-
body-coated tumor cells and membrane-bound
Fcc receptors expressed on the surface of
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effector cells (natural killer cells, granulocytes,
and macrophages) [37]. This interaction triggers
the onset of cellular immune responses central
to ADCC, including the release of cytokines,
chemokines, and mediators that kill target cells.
In addition, rituximab binding to CD20 on B
lymphocytes is thought to induce cell death via
nonclassical apoptosis by triggering the
crosslinking of multiple CD20 molecules
[34–36].
Fig. 1 Mechanisms of rituximab-mediated cell death.
Rituximab-coated B cells are killed by at least four
different mechanisms: (1) binding of rituximab to CD20
on the B-cell surface causes activation of the complement
cascade, which generates the membrane attack complex
(MAC), which can directly induce B-cell lysis by comple-
ment-dependent cytotoxicity (CDC). (2) Binding of
rituximab allows interaction with natural killer (NK) cells
via Fc receptors (FcRs) III, which leads to antibody-de-
pendent cellular cytotoxicity (ADCC). (3) The Fc portion
of rituximab and the deposited complement fragments
allow recognition by both FcRs and complement receptors
on macrophages, which leads to phagocytosis and ADCC.
(4) The crosslinking of several molecules of rituximab and
CD20 in the lipid raft determines the interaction of these
complexes with elements of a signaling pathway involving
Src kinases that mediate direct apoptosis. FCR Fc receptor,
FCcR Fcc receptor. (Republished with permission of the
American Society of Hematology from Jaglowski et al.
[166]; permission conveyed through the Copyright Clear-
ance Center)
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PHARMACODYNAMICS
OF RITUXIMAB
Potent B-cell-depleting activity in peripheral
blood and lymphoid tissues was reported with
rituximab in phase I and phase II studies
[38, 39]. Circulating CD20? B cells underwent
rapid depletion in the peripheral blood of
patients with recurrent B-cell lymphoma treated
with a single dose of rituximab. This effect was
dose dependent and persisted for at least 2–
3 months in most patients. In addition, there
was evidence of a fall in the number of B cells in
lymph node biopsy samples 2 weeks after
administration of rituximab compared with
pretreatment [38]. In a second group of patients
with relapsed low-grade NHL treated with mul-
tiple doses of rituximab, B-cell depletion was
maintained until nearly 6 months after treat-
ment, followed by a slow recovery [39].
PHARMACOKINETIC PROFILE
OF RITUXIMAB
The pharmacokinetic (PK) profile of rituximab
in a variety of B-cell malignancies has been
characterized throughout the product’s life
cycle, with use of original data from clinical
studies as described herein, and by integration
of these data into population PK analyses.
Among patients with low-grade or follicular
NHL treated with intravenously administered
rituximab, serum concentrations of rituximab
were detectable after the first infusion and
increased with subsequent administrations
[38–40]. In 203 patients with relapsed low-grade
lymphoma who received four weekly intra-
venous infusions of rituximab (375 mg/m2) in
two clinical studies [39, 40], the mean maxi-
mum plasma concentration (Cmax) of rituximab
was 486 lg/mL (range 77.5–996.6 lg/mL) after
the fourth dose, and the drug was detectable in
serum for up to 6 months after completion of
dosing [29, 30]. In another study, the median
serum rituximab concentration after the last of
four weekly infusions in a group of 22 FL
patients with low tumor burden was approxi-
mately 380 lg/mL, and the study authors
predicted a steady-state plasma concentration
in this group of 438 lg/mL if the drug had been
administered once weekly for 8 weeks [41].
Elimination of rituximab in patients with
B-cell malignancies is target mediated (i.e.,
binding of the drug to CD20 on B cells clears the
antibody from the serum during the initial
infusions, leading to a reduction in or satura-
tion of accessible CD20-binding sites at lymph
nodes). This was seen in the phase III study by
Berinstein et al. [40], which found a marked
increase in mean elimination half-life (t1/2)
from 76.3 to 205.8 h from the first to the fourth
rituximab infusion, which corresponded to a
nearly fourfold decrease in clearance (from 38.2
to 9.2 mL/h) and an increase in rituximab Cmax
from 205.6 to 464.7 lg/mL. Later studies
reported even slower clearance (i.e., t1/2 for
rituximab of approximately 3 weeks), although
with large intersubject variability [41, 42]; total
systemic clearance was estimated at
3.1–11.9 mL/h/m2 in the earlier study [41].
No notable differences were observed
between the PK profiles of rituximab when it
was administered as monotherapy and when
rituximab therapy was combined with
cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) chemotherapy [43]. A
population PK analysis in 298 patients with
NHL from six clinical studies who were treated
with rituximab alone or rituximab combined
with CHOP (R-CHOP) showed that age, sex,
race, and WHO performance status had no
effect on rituximab pharmacokinetics [44].
Higher B-cell counts and greater baseline tumor
burden were associated with increased clearance
rates, and the volume of distribution varied
depending on body surface area and CHOP
chemotherapy. Rituximab elimination was
reduced following multiple infusions. This
analysis found that the PK profile of rituximab
in NHL patients is best described by a
two-compartment model with a nonspecific
time-independent clearance component and a
time-dependent clearance component exhibit-
ing first-order kinetics [44].
In a population PK analysis in previously
treated patients with relapsed or refractory CLL
treated with rituximab (375 mg/m2 in cycle 1
then 500 mg/m2 in cycles 2–6) and
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standard-dose fludarabine and cyclophos-
phamide (FC), PK data for rituximab in 21
patients showed a time-dependent PK profile
with wide interpatient variability [45]. The
study authors noted differences in PK parame-
ters in these CLL patients compared with
patients with NHL from a previous population
analysis [44]: CLL patients had faster clearance
(1260 mL/day vs 585 mL/day), a larger volume
of distribution (central 4150 mL vs 2700 mL,
peripheral 2320 mL vs 1500 mL), and a lower
rate of change from the target-mediated clear-
ance pathway (via CD20) to catabolic elimina-
tion (via IgG1) compared with NHL patients
[45].
Rituximab serum concentrations have been
reported to correlate with clinical response. In a
detailed analysis of 166 patients with low-grade
or follicular NHL, median serum concentrations
of rituximab were higher in responders than in
nonresponders after each of the four weekly
infusions and up to 3 months after treatment
(e.g., 502.8 and 412.4 lg/mL, respectively, after
the fourth infusion; P = 0.01) [40]. There was an
inverse relationship between serum rituximab
concentrations and baseline tumor burden
indicators. Linear regression showed the inverse
correlation between absolute levels of circulat-
ing peripheral B cells at the baseline and ritux-
imab concentration to be statistically
significant from the second infusion until
1 month after treatment. Inverse correlations
between rituximab concentrations in serum and
(1) the maximum diameter of the largest lesion
and (2) the sum of the product of the perpen-
dicular diameters of the six largest lesions were
statistically significant at all time points mea-
sured with the exception of the period follow-
ing the first infusion.
A similar relationship between exposure and
response was seen in a phase II study of 68
Japanese patients with aggressive B-cell lym-
phoma [46]. Serum rituximab concentrations
were evaluated in seven responders and five
nonresponders. The mean (± standard devia-
tion) trough levels and areas under curves of
serum antibody concentration versus time
(AUC) for responders and nonresponders were
59.7 ± 11.4 and 43.0 ± 6.4 lg/mL, respec-
tively, and 608,585 ± 147,373 and 383,053 ±
176,903 lg h/mL, respectively, with significant
differences between groups (P = 0.021 and
P = 0.037). Pretreatment tumor size (sum of the
product of the perpendicular diameters) was
inversely correlated with AUC (P\0.05 by
Spearman’s rank correlation coefficient).
Other studies have shown that rituximab
exposure falls as tumor volume increases, and
that higher exposure correlated with better
response and/or outcome [47–50]. A recent
report from Tout et al. [50] in 108 previously
untreated DLBCL patients demonstrated that
rituximab exposure decreased as baseline total
metabolic tumor volume increased, with a high
AUC in cycle 1 being associated with better PET
response after cycle 4 (odds ratio 5.56,
P = 0.0006) and longer progression-free-survival
(PFS; hazard ratio, HR, 0.38, P = 0.011) and
overall survival (OS; HR 0.17, P = 0.001). Sex
and body weight may also influence rituximab
pharmacokinetics [51, 52]. In a study of 20
elderly patients (aged 61–79 years) with DLBCL,
Mu¨ller et al. [51] found that rituximab clearance
was reduced and t1/2 increased in women com-
pared with men. In addition, the volume of
distribution increased by 0.1 L/kg for body
weights greater than 75 kg. Although the ben-
efit from addition of rituximab to chemother-
apy is similar in younger male and female
patients, this does not seem to hold true for
older patients, with elderly female patients
benefitting more than elderly male patients
[52]. Swedish registry data have shown similar
patterns, with possibly inadequate dosing in
younger female patients, and male patients of
all ages [53].
MANUFACTURE OF RITUXIMAB
Rituximab is produced in suspension culture by
a Chinese hamster ovary transfectoma con-
taining the TCAE 8 expression vector in a
nutrient medium. Process and product impuri-
ties such as high molecular weight aggregates
are then removed by protein A affinity chro-
matography and anion exchange chromatogra-
phy. The purified rituximab is then formulated
as an aqueous concentrate for intravenous
administration under sterile conditions, in a
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mixture of sodium chloride (9.0 mg/mL),
polysorbate 80 (0.7 mg/mL), sodium citrate
dihydrate (7.35 mg/mL), and water (solution pH
6.5, rituximab concentration 10 mg/mL), and
packaged in 10- or 50-mL borosilicate glass
vials. As the vials are designed for single use, no
preservatives are added to the formulation. An
unopened vial has a shelf life of 30 months
when stored at the recommended temperature
of 2–8C.
CLINICAL EFFICACY OF RITUXIMAB
Rituximab in Follicular Lymphoma
The initial regulatory approval of rituximab in
1997 in FL was based on data from a pivotal
phase II trial of rituximab monotherapy in 166
patients with relapsed or refractory low-grade
NHL. The overall response rate (ORR) in this
trial was 48% [complete response (CR) rate 6%],
and the median time to progression for the
intent-to-treat population was 13.0 months
[54]. Several other trials published between
1997 and 2000 showed similar results in
relapsed/refractory low-grade NHL, with overall
tumor response rates ranging from 38% to 47%
after 4 weeks’ treatment with rituximab [55–57],
and 57% after 8 weeks’ treatment [58]. Each of
these studies involved between 30 and 70
patients.
More recently, a 74% ORR and a 28% CR
rate, with median PFS of 23.5 months and
91.7% OS rate after 7 years of follow-up, were
reported in 46 patients with low tumor burden
disease after first-line induction therapy with
four weekly doses of rituximab at 375 mg/m2
[59]. Two phase III studies in larger numbers of
patients have also shown activity of rituximab
monotherapy. Taverna et al. [60] reported a
16.9% CR/unconfirmed CR rate in 261 patients
undergoing induction therapy with four doses
of rituximab (this study included patients with
previously untreated and relapsed/refractory
disease). Subsequent short-term (four doses;
n = 82) or long-term (5 years or less; n = 83)
rituximab maintenance therapy yielded median
event-free survival (EFS) of 3.4 and 5.3 years,
respectively (P = 0.14). In a trial in patients with
advanced disease receiving four doses of ritux-
imab alone (n = 156) or in conjunction with
interferon alfa (n = 157) [61], there was a 78%
ORR to an initial cycle of treatment. Responders
who received a second cycle showed CR/un-
confirmed CR rates of 21% and 41%, respec-
tively (P = 0.005). The median times to
treatment failure were 28 and 21.5 months,
respectively (P = 0.302).
Since then, substantial clinical benefit has
been reported in FL patients from the incorpo-
ration of rituximab into induction chemother-
apy regimens in both the first-line setting
[62–70] and in previously treated patients
[62, 71].
Induction treatment with rituximab and
chemotherapy has been shown to be superior to
chemotherapy alone in several large-scale trials
(typical treatment duration of 6 months),
mainly conducted in previously untreated
patients with stage III/IV FL, consistently
achieving better results in terms of ORR, CR,
time to treatment failure, PFS, and OS (Table 1).
A variety of chemotherapy regimens were
combined with rituximab therapy in these
studies, including CHOP, cyclophosphamide,
vincristine, and prednisolone (CVP), and
mitoxantrone, chlorambucil, and prednisone
(MCP) regimens. On the basis of the body of
evidence provided by these studies, rituximab
therapy plus chemotherapy has been adopted
worldwide as the standard of care for the first-
line treatment of patients with FL [10, 22], and
the worldwide indications for rituximab are
reflective of this.
The use of rituximab maintenance therapy
to preserve responses to induction therapy in
responding patients, and to further enhance
clinical outcomes, has also been demonstrated
in previously untreated patients with advanced
FL, as demonstrated in the Eastern Cooperative
Oncology Group (ECOG) 1496 and PRIMA trials
[72–74]. In these two studies, previously
untreated patients with advanced FL who had
responded to either CVP (ECOG 1496) or one of
three rituximab–chemotherapy induction
treatment regimens [rituximab plus CVP, R-
CHOP, or rituximab plus fludarabine,
cyclophosphamide, and mitoxantrone (R-FCM);
PRIMA] were randomized to receive rituximab
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Table 1 Summary of key studies evaluating rituximab-based immunochemotherapy in patients with previously untreated or
relapsed/refractory follicular lymphoma
Study reference Line of therapy
and no. of
patients
Treatment
regimen
ORR CR PFS, EFS, or other
parameter as
indicateda
OS
GLLSG
Hiddemann et al.
[63]
1L (428) R-CHOP vs
CHOP
96% vs
90%b
20% vs
17%
TF (median
observation time
18 months):
12.6% vs 29.8%b
Deaths:
2.7% vs
8.3%b
East German Study
Group
Herold et al. [64]
1L (201) R-MCP vs MCP 92% vs
75%b
50% vs
25%b
EFS: NR vs
26 monthsb
PFS: NR vs
28.8 monthsb
mFU: 47 months
4-year: 87%
vs 74%b
Marcus et al. [65]
Marcus et al. [66]
1L (321) R-CVP vs CVP 81% vs
57%b
41% vs
10%b
TTF: 27 months vs
7 monthsb
DFS: NR vs
21 monthsb
mFU: 30 months
4-year: 83%
vs 77%b
GELA-GOELAMS
FL2000
Salles et al. [67]
Bachy et al. [68]
1L (358) R-CHVP ? INF
vs
CHVP ? INF
81% vs
72%b
51% vs
39%b
EFS: 5.5 years vs
2.8 yearsb
5-year EFS: 53% vs
37%b
8-year EFS: 44% vs
28%b
mFU: 5 and 8.3 years
5-year: 84%
vs 79%
8-year: 79%
vs 70%
FOLL05
Federico et al. [69]
1L (504) R-CVP vs
R-CHOP
vs R-FM
88% vs
93% vs
91%
67% vs
73% vs
72%
3-year TF: 46% vs
62% vs 59%
HR 0.62, R-CHOP
vs R-CVPb,c, HR
0.63, R-FM vs
R-CVPb
3-year PFS: 52% vs
68% vs 63%
HR 0.64, R-CHOP
vs R-CVPb,c, HR
0.66, R-FM vs
R-CVPb,c
mFU: 34 months
3-year: 95%
(all
patients)
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maintenance therapy for 2 years or observation.
In the ECOG 1496 study, rituximab mainte-
nance therapy achieved a significantly higher
3-year PFS rate than observation (64% vs 33%;
HR 0.4, P\0.001) [72]. OS at 3 years was,
however, comparable between the two arms
(91% vs 86%; HR 0.6, P = 0.08). In the PRIMA
trial, the 3-year PFS rate was 74.9% in the
rituximab maintenance therapy arm compared
with 57.6% for patients randomized to undergo
observation (HR 0.55, P\0.001) [73], and
long-term follow-up (median of 73 months)
showed that the PFS benefit achieved with
rituximab maintenance therapy was main-
tained after 6 years (59.2% vs 42.7%; HR 0.58,
P\0.0001) [74]. Six-year OS in the PRIMA trial
was favorable with both rituximab maintenance
therapy and observation, and did not differ
significantly between the two arms. Neither
median PFS nor median OS had been reached in
the rituximab maintenance therapy arm at the
6-year follow-up.
The RESORT trial compared the efficacy of
rituximab maintenance therapy with rituximab
Table 1 continued
Study reference Line of therapy
and no. of
patients
Treatment
regimen
ORR CR PFS, EFS, or other
parameter as
indicateda
OS
Rummel et al. [70] 1L (514: 420
NHL,
including 279
FL; 94 MCL)
R ? benda vs
R-CHOP
93% vs
91%
40% vs
30%b
PFS: 69.5 months vs
31.2 months
(HR 0.58)
mFU: 45 months
Deaths:
16.5% vs
17.8%
Czuczman et al.
[62]
1L and 2L (38) R-CHOP 100% (1L
100%,
R/R
100%)d
87% (1L
90%,
R/R
78%)d
TTP: 82.3 months
mFU: NA
EORTC 20981
van Oers et al. [71]
R/R (465) R-CHOP vs
CHOP
85.1% vs
72.3%b
29.5% vs
15.6%b
PFS: 33.1 months vs
20.2 months
(HR 0.65b)
mFU: 39.4 months
3-year:
82.5% vs
71.9%
(HR
0.74)
All studies were phase III randomized trials except for the study of Czuczman et al. [62], which was a single-arm phase II
study
benda bendamustine, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, CHVP cyclophosphamide,
doxorubicin, etoposide, and prednisone, CR complete response, CVP cyclophosphamide, vincristine, and prednisone, DFS
disease-free survival, EFS event-free survival, EORTC European Organisation for Research and Treatment of Cancer, FL
follicular lymphoma, FM fludarabine and mitoxantrone, GELA Groupe d’Etude des Lymphomes de l’Adulte, GLLSG
German Low-Grade Lymphoma Study Group, GOELAMS Groupe Ouest Est des Leuce´mies et Autres Maladies du Sang,
HR hazard ratio, INF interferon, 1L first line, 2L second line MCL mantle cell lymphoma, MCP mitoxantrone, chlo-
rambucil, and prednisone, mFU median follow-up, NA not available, NHL non-Hodgkin lymphoma, NR not reached, ORR
overall response rate, OS overall survival, PFS progression-free survival, R rituximab, R/R relapsed/refractory, TF treatment
failure, TTF time to treatment failure, TTP time to progression
a Median values
b Statistically significant difference
c HR adjusted by Follicular Lymphoma International Prognostic Index 0–2 vs 3–5
d Updated values assessed according to International Workshop response criteria
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retreatment in 545 patients with previously
untreated FL and a low tumor burden [75]. The
study found no difference between groups in
terms of the primary end point, time to treat-
ment failure (this outcome measure was defined
as a lack of response to rituximab retreatment),
time to progression of less than 26 weeks,
commencement of alternative treatment, or an
inability to complete planned treatment [75].
The lack of a significant benefit of rituximab
maintenance therapy over rituximab retreat-
ment may have been because the primary end
point favored the retreatment arm or because
the study was conducted in patients with low
tumor burden, in contrast to the PRIMA study
[73, 74], which was conducted in patients
requiring treatment.
Similarly, in the relapsed/refractory FL set-
ting, significant improvements in efficacy have
been reported with rituximab induction ther-
apy plus chemotherapy and rituximab mainte-
nance therapy compared with standard
chemotherapy (Table 2) [71, 76–79]. For exam-
ple, superior outcomes were reported with
R-FCM compared with fludarabine, cyclophos-
phamide, and mitoxantrone (FCM) in patients
with relapsed/refractory FL or MCL enrolled in a
phase III study conducted by the German
Low-Grade Lymphoma Study Group [76]. In all
study patients, the addition of rituximab to
FCM induction therapy significantly increased
ORR (79% vs 58%; P = 0.01), median PFS
(16 months vs 10 months; P = 0.04), and med-
ian OS (not reached vs 24 months; P\0.01)
compared with FCM alone [76]. A second ran-
domization, to rituximab maintenance therapy
or observation in patients who had responded
to induction therapy, showed a significant
prolongation of response duration with main-
tenance treatment (median, not reached vs
17 months; P\0.001) [77]. The phase III Euro-
pean Organisation for Research and Treatment
of Cancer 20981 trial included an induction
phase during which patients with relapsed/re-
fractory FL were randomized to receive R-CHOP
or CHOP, followed by randomization to ritux-
imab maintenance therapy or observation for
those patients who responded to induction
therapy [71, 78]. The study investigators repor-
ted a significant increase in ORR (85% vs 72%;
P\0.001) and PFS (33.1 months vs
20.2 months; HR 0.65, P\0.001), and a trend
toward an increase in 3-year OS rate (83% vs
72%; HR 0.74, P = 0.096) with R-CHOP com-
pared with CHOP induction therapy. Rituximab
maintenance therapy subsequently achieved a
significant improvement in median PFS com-
pared with observation (51.5 months vs
14.9 months; HR 0.40, P\0.001); the 5-year OS
rate was also greater with rituximab mainte-
nance therapy (74% vs 65%; HR 0.70, P = 0.07),
but the difference between the two arms did not
achieve statistical significance. The investiga-
tors cited the unbalanced use of rituximab in
postprotocol salvage treatment as a possible
reason for this finding [78]. A similar pattern of
results was reported in the phase III SAKK 35/98
trial evaluating induction therapy with sin-
gle-agent rituximab followed by rituximab
maintenance therapy or observation (Table 2)
[79], further confirming the benefit of ritux-
imab maintenance therapy in patients with
relapsed/refractory FL. In a meta-analysis of
data from 2315 patients in seven randomized
trials, survival was significantly improved with
rituximab maintenance therapy compared with
observation only (HR 0.79, 95% confidence
interval 0.66–0.96) for all categories of patients
except those receiving first-line therapy that
included rituximab induction therapy [80].
Watchful waiting until disease progression
occurs has conventionally been used in FL
patients with advanced disease with low tumor
burden [81]. The use of rituximab in this setting
to delay the need for chemotherapy or radio-
therapy was explored in a multinational phase
III study in 463 patients who underwent
watchful waiting, rituximab induction therapy
(375 mg/m2 weekly for 4 weeks), or rituximab
induction therapy followed by 2 years’ mainte-
nance therapy [82]. Of the patients in the
watchful waiting group, 46% had not needed
new treatment at 3 years, compared with 88%
in the rituximab maintenance therapy group
(HR 0.21, P\0.0001). Significantly more
patients in the induction therapy group than in
the watchful waiting group (78%) had not
needed new treatment at 3 years (HR 0.35,
P\0.0001), whereas the proportion not need-
ing new treatment was similar in the
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maintenance therapy and induction therapy
groups (HR 0.75, P = 0.33). The place of ritux-
imab therapy relative to watchful waiting in FL
remains under discussion in the literature [83].
Rituximab in Diffuse Large B-Cell
Lymphoma
Rituximab is currently approved in Europe and
the USA for previously untreated CD20? DLBCL
in combination with CHOP or other anthracy-
cline-based chemotherapy and is also included
in current treatment guidelines in combination
with salvage chemotherapy for relapsed/refrac-
tory disease [9, 22]. A phase II trial of R-CHOP as
first-line treatment in patients with aggressive
NHL (67% with DLBCL) was the first study to
demonstrate the feasibility and safety of R-
CHOP in this population, with an ORR of 94%
and 20 of 33 patients (61%) having a CR [84].
Two pivotal phase III randomized trials
established R-CHOP therapy as the standard of
care for elderly patients with DLBCL [85, 86]
(Table 3). In a study conducted by the Groupe
d’Etude des Lymphomes de l’Adulte (GELA;
LNH98-5), previously untreated elderly patients
(aged 60–80 years) with DLBCL were randomized
to receive eight cycles of R-CHOP or CHOP
therapy [85]. Sixty percent of patients were
deemed to be poor risk, with age-adjusted IPI
scores of 2 or 3. The CR rate was significantly
higher in favor of R-CHOP (76% vs 63%;
P = 0.005). The proportions of patients with EFS
(disease progression or relapse, institution of new
treatment, or any-cause death) at 2 years (57% vs
38%; HR 0.58, P\0.001) and OS at 2 years (70%
vs 57%; HR 0.64, P = 0.007) also favored R-
CHOP. In a second phase III study (ECOG 4494/
US Intergroup study), DLBCL patients aged
60 years or older were randomized to receive R-
CHOP or CHOP, followed by a second random-
ization for responding patients to rituximab
maintenance therapy or observation [86]. The
proportion of patients with failure-free survival
(FFS; time from randomization to relapse, non-
protocol treatment, or death) at 3 years was sig-
nificantly higher with R-CHOP than with CHOP
(53% vs 46%; HR 0.78, P = 0.04). In addition, the
2-year FFS rate from the second randomization
was 76% for rituximab maintenance therapy
compared with 61% for observation (P = 0.009).
Subanalyses showed that rituximab maintenance
therapy significantly prolonged FFS after CHOP
therapy (HR 0.45, P = 0.0004) but not after R-
CHOP therapy, thus implying that rituximab
maintenance therapy after rituximab-based
immunochemotherapy does not provide addi-
tional clinical benefit in patients aged 60 years or
older with DLBCL. No significant differences in
OS were reported.
In terms of younger patients, the MabThera
International Trial (MInT) Group confirmed the
benefit of adding rituximab therapy to CHOP
chemotherapy compared with CHOP
chemotherapy alone (given for a total of six
cycles) in patients aged 18–60 years with previ-
ously untreated, good-prognosis DLBCL
[87, 88]. R-CHOP therapy was associated with a
significant increase in 3-year EFS rate (79% vs
59%; P\0.0001), 3-year PFS rate (85% vs 68%;
P\0.0001), and 3-year OS rate (93% vs 84%;
P = 0.0001) compared with CHOP chemother-
apy alone [87] (Table 3). In the R-CHOP and
CHOP groups, patients considered to be at low
risk (IPI score of 0 and no bulky disease) had
significantly longer EFS than those at higher risk
(IPI score of 1, bulky disease, or both). Impor-
tantly, subsequent follow-up reports from the
GELA trial and MInT indicated that the benefi-
cial effect of R-CHOP therapy over CHOP
chemotherapy alone was sustained over the
longer term in both older patients (GELA trial,
5-year OS rate 58% vs 45%, P = 0.007; 10-year
OS rate 44% vs 28%, P\0.0001) [89, 90] and
younger patients (MInT, 6-year OS rate 90% vs
80%, P = 0.0004) [88]. Comparison of rituximab
maintenance therapy and observation only in
the randomized NHL-13 trial, which enrolled
683 patients with DLBCL who had responded to
first-line rituximab therapy plus CHOP-like
chemotherapy, showed no difference in the
primary end point of EFS after a median fol-
low-up of 45 months [91]; however, PFS was
significantly improved in the maintenance
therapy arm relative to the observation arm.
Salvage chemotherapy may be an option for
patients with DLBCL that is refractory to
induction therapy or who subsequently relapse
after achieving a CR. As monotherapy,
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rituximab achieved promising response rates in
54 patients, mostly with relapsed/refractory
DLBCL, in a phase II study [92]. Subsequently,
rituximab was evaluated in combination with a
variety of salvage chemotherapy regimens in
phase II and phase III studies in this setting,
including ifosfamide, carboplatin, and etopo-
side (ICE), dexamethasone, cytosine arabi-
noside, and cisplatin (DHAP), and etoposide,
ifosfamide, and methotrexate (VIM) regimens
(Table 3). In a randomized phase III study, the
addition of rituximab therapy to DHAP–
VIM–DHAP therapy followed by autologous
stem cell transplantation in 225 patients with
relapsed or refractory aggressive NHL resulted in
a significant improvement in FFS and PFS
compared with chemotherapy alone [93]. The
second randomized phase III trial, in 396
patients, demonstrated similar efficacy results
for rituximab plus ICE and rituximab plus
DHAP but did not include a chemotherapy-only
arm; the study authors considered that neither
regimen offered any benefit over other ritux-
imab-based regimens given before or after
autologous stem cell transplantation in previ-
ous studies [94]. Other studies in this setting
were smaller in scale (50 or fewer patients) and
did not include control arms [95–98]; however,
the findings from two of these studies suggested
potential benefits from the addition of ritux-
imab therapy to chemotherapy when compared
with historical data [95, 96] (Table 3).
Rituximab in Chronic Lymphocytic
Leukemia
In Europe and the USA, intravenously adminis-
tered rituximab is approved in combination with
chemotherapy for the treatment of patients with
previously untreated and relapsed/refractory CLL
[11, 23, 29, 30]. Two large phase III randomized
studies investigating the concurrent administra-
tion of rituximab plus FC (R-FC) compared with
FC alone were conducted in patients with CLL
[99, 100] (Table 4). Both studies were initiated on
the basis of the findings of earlier phase I/II
monotherapy and combination chemotherapy
studies [101–106]. In the CLL8 trial, R-FC was
compared with FC alone in patients with CLL
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who had not received any prior chemotherapy
[99]. Median PFS was significantly prolonged (by
19 months) with R-FC compared with FC (HR
0.56, P\0.0001), with results favoring R-FC for
all three Binet stage subgroups. A significant
benefit in favor of R-FC over FC was also
observed in terms of OS (HR 0.67, P = 0.012),
and ORR and CR rate (P\0.0001) [99]. In an
updated analysis of the CLL8 trial, median PFS
with R-FC was almost twice as long as with FC
(56.8 months vs 32.9 months; HR 0.59,
P\0.001) and median OS was also significantly
prolonged (R-FC, not reached; FC, 86.0 months;
HR 0.68, P = 0.001) [107]. In previously treated
patients with CLL in the REACH study, R-FC
treatment was associated with a 10-month
improvement in median PFS compared with FC
(30.6 months vs 20.6 months; HR 0.65,
P\0.001) [100]. Consistent with the CLL8
study, improvements in PFS in the R-FC arm
were also associated with significant increases in
both the ORR and the CR rate. On the basis of
the findings from these studies, R-FC became a
first-choice treatment for patients with newly
diagnosed or relapsed CD20? CLL. Indeed, R-FC
may be able to affect a cure in a subset of CLL
patients with favorable genetic profiles: long-
term follow-up of patients treated with R-FC in
clinical trials has shown that those with mutated
Ig heavy chain variable region gene status and
without the 17p and 11q deletions achieve very
long remissions [107–109].
Data from other, mostly phase II studies
evaluating rituximab combination therapy in
patients with previously untreated and
relapsed/refractory CLL have also been pub-
lished, and are summarized in Table 4. These
data are consistent with the results of the CLL8
and REACH studies, and provide further con-
firmation of the clinical efficacy of R-FC in CLL
[105, 106, 110–113]. Promising results have also
been reported with the combination of ritux-
imab and bendamustine in a phase II study
involving patients with both previously
untreated and relapsed/refractory CLL
[114, 115]. However, recently published data
from the phase III CLL10 trial in 564 previously
untreated, fit CLL patients showed that ritux-
imab plus bendamustine was associated with
significantly shorter PFS than R-FC (median
41.7 months vs 55.2 months; HR 1.64,
P = 0.0003) [116]. Although there was a clear
difference in PFS between the two study treat-
ments in the overall patient population, sub-
group analyses showed that the PFS benefit in
the R-FC arm was significant only in younger
patients (65 years or younger). Additionally, the
tolerability (notably the incidence of severe
infections) was better with rituximab plus ben-
damustine, particularly among patients older
than 65 years. Taken together, these findings
suggest that although R-FC may be the more
effective regimen overall, rituximab plus ben-
damustine may have a role in the treatment of
fit, older patients with CLL.
Another widely used treatment option for
less fit patients with CLL is rituximab plus
chlorambucil. In two phase II studies in previ-
ously untreated patients who received the
combination (n = 85 and 100), adverse event
(AE) profiles were favorable, and ORRs of up to
84% were achieved, with CR rates of 17% and
10% [117, 118].
The potential benefit of rituximab mainte-
nance therapy in CLL has also been explored in
a small number of studies, with some encour-
aging results [119–121]. In a phase II study in
previously untreated CLL patients, for example,
4-year PFS and OS rates were 74.8% and 93.7%,
respectively, in 67 patients who received ritux-
imab maintenance therapy after responding to
R-FCM induction therapy, compared with
69.1% and 90.5%, respectively, for the patient
population overall (n = 81; treated with R-FCM
as induction therapy with or without rituximab
maintenance therapy) [120]. Results from the
randomized CLL 2007 SA trial of 2 years of
rituximab maintenance therapy versus obser-
vation following induction therapy with four
cycles of R-FC therapy in patients aged 65 years
or older included a significant improvement in
median PFS (59.3 months vs 49.0 months; HR
0.60, P = 0.001). Rituximab maintenance ther-
apy also improved PFS in patients with genetic
markers indicative of poorer prognosis,
although no difference in 3-year OS was seen,
and maintenance treatment was associated with
a greater incidence of AEs [121]. In addition,
studies are ongoing to determine the efficacy
and safety of rituximab in combination with
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newer agents such as inhibitors of Bruton’s
tyrosine kinase and phosphoinositide 3-kinase,
as well as inhibitors of the mechanistic target of
rapamycin, and BCL2 inhibitors [122–125].
However, approval of these new drugs could be
many years away in many countries, and in
those with more limited healthcare budgets, the
cost of these agents is likely to be prohibitive;
for this reason, immunochemotherapy with
rituximab combined with FC, bendamustine, or
chlorambucil will continue to be a mainstay of
patient treatment.
Other B-Cell Malignancies
Encouraging results have also been reported in
four studies of rituximab in other B-cell malig-
nancies for which use of the drug is not yet
licensed.
In the final report of the randomized
IELSG-19 study in 454 patients with extranodal
marginal-zone B-cell lymphoma, a combination
of rituximab and chlorambucil was associated
with significantly longer EFS and PFS than
chlorambucil or rituximab alone after a median
follow-up of 7.4 years [126]. In a randomized
phase III trial of 52 nonfollicular indolent NHL
patients with low tumor burden who responded
to rituximab induction therapy, those who
received 3-monthly rituximab maintenance
therapy had a 3.5-fold longer time to treatment
failure than those who received retreatment at
the time of progression [127]. In two other trials
that assessed the addition of rituximab therapy
to chemotherapy in highly aggressive lymphoid
malignancies, significant increases in EFS rela-
tive to chemotherapy alone were seen in 209
patients with CD20?, Philadelphia chromo-
some-negative acute lymphoblastic leukemia
after a median follow-up of 30 months [128],
and in 260 patients with previously untreated
Burkitt lymphoma after a median follow-up of
38 months [129].
Rituximab has also been shown to improve
OS in older patients with MCL, both in the
first-line setting when added to induction
chemotherapy and when used as maintenance
therapy after rituximab therapy plus
chemotherapy as induction therapy [130, 131].
Additional B-cell malignancies in which ritux-
imab treatment has been associated with posi-
tive outcomes in phase II and phase III clinical
trials include Waldenstro¨m macroglobulinemia,
posttransplant lymphoproliferative disorders,
and Hodgkin lymphoma [132–134]. Rituximab
is not yet licensed for use in any of these
diseases.
Development of Resistance to Rituximab
Although the efficacy of rituximab for the
treatment of B-cell hematologic malignancies is
well established, some patients do not respond
to first-line treatment, and others experience
relapse after initial response to therapy
[54, 135].
Despite many years of study, the exact
mechanisms underlying the development of
resistance to rituximab remain unclear. How-
ever, given the reliance of rituximab on
immune-effector mechanisms for its antitumor
efficacy, it has been hypothesized that intrinsic
tumor cell alterations and the host immuno-
logic environment may both play a role. There
are many postulated in vivo mechanisms of
resistance, and these are described in detail
elsewhere [136, 137]. In brief, they include
inhibition of three of the pathways that are
involved in the mechanism of action of ritux-
imab; namely, CDC, ADCC, and apoptosis.
Complement depletion, through exhaustion of
the store of complement proteins, has been
implicated in the development of resistance to
rituximab-mediated CDC. Furthermore, host
immunologic factors, such as polymorphism of
Fcc receptor IIIa on cytotoxic cells, may affect
the sensitivity of tumor cells to ADCC, whereas
alterations in apoptotic pathway signaling,
through overexpression of antiapoptotic gene
products, may facilitate the development of
apoptosis resistance in the presence of ritux-
imab [136, 137]. Another possible mechanism
of rituximab resistance is loss of the CD20 target
antigen, which has been demonstrated in lym-
phoma cell lines and in biopsy samples from
relapsed patients [138, 139]. This phenomenon
may occur in several ways, including decreased
expression at both the pretranslational level
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and the posttranslational level, antigenic mod-
ulation (whereby CD20 antibody–antigen
complexes are internalized following rituximab
binding), or the acquisition of CD20 mutations.
Removal of rituximab/CD20 complexes from
the B-cell surface by monocytes in a process
called ‘‘trogocytosis’’ or ‘‘CD20 shaving’’ has also
been reported [140]. In addition, generation of
rituximab-resistant clones, the tumor microen-
vironment, and the PK profile of rituximab may
also have a role in the development of ritux-
imab resistance [136, 137].
Patients treated with rituximab may develop
an antibody against rituximab, termed ‘‘human
antichimeric antibody.’’ These patients have the
potential to mount allergic reactions when
subsequently treated with other antibodies. To
date, immune responses against rituximab have
been much more common in patients treated
for rheumatoid arthritis than in those with
other diseases. During clinical trials in patients
with B-cell malignancies, up to 2% of patients
developed human antichimeric antibody, but
no effect of this antibody on the efficacy or
safety of rituximab has been demonstrated
[29, 30].
Various strategies are being investigated to
overcome rituximab resistance. One such
approach is the use of adjuncts to inhibit
hyperactivated survival/antiapoptotic path-
ways, which regulate downstream antiapoptotic
gene products. Possible candidates include his-
tone deacetylase inhibitors, targeted chemical
inhibitors, proteasome inhibitors, selective
inhibitors for antiapoptotic gene products, and
microRNAs [137]. The combination of ritux-
imab and lenalidomide, an immunomodulatory
drug that has been shown to enhance ADCC in
in vitro and in vivo leukemia models, has
demonstrated efficacy in patients with indolent
B-cell lymphomas, DLBCL, and CLL who were
rituximab resistant or had previously relapsed
following rituximab therapy [141–144].
Another important avenue of research to
counter rituximab resistance is the develop-
ment of novel, next-generation anti-CD20
mAbs with different mechanisms of action. This
approach is exemplified by obinutuzumab, a
second-generation type II anti-CD20 mAb,
which has recently been approved in
combination with bendamustine followed by
single-agent maintenance therapy for the
treatment of patients with FL who do not
respond to or whose disease progresses after
treatment with rituximab or a rituximab-con-
taining regimen [145].
SAFETY AND TOLERABILITY
OF RITUXIMAB IN PATIENTS
WITH HEMATOLOGIC
MALIGNANCIES
Overview of the Safety Profile
With 20 years of postmarketing surveillance
experience and more than four million patient
exposures, the safety profile of rituximab, both
as monotherapy (induction and/or mainte-
nance) and in combination with chemother-
apy, in the treatment of patients with B-cell
hematologic malignancies is very well defined.
Furthermore, in the two decades since the reg-
ulatory approval of rituximab, no new or
unexpected safety signals have been identified,
thus confirming a favorable therapeutic
window.
From clinical trial and postmarketing
surveillance data from patients with NHL and
CLL, infusion-related reactions (IRRs) were
identified as the most common adverse drug
reactions (ADRs) in patients treated with ritux-
imab as monotherapy or combination therapy
[29, 30]. In those studies, IRRs of any grade and
type, including cytokine-release syndrome,
were observed in 77% of patients. Severe IRRs
(grade 3 or 4), including bronchospasm and
hypotension, were reported in 12% of patients
[29]. Although rare, fatal reactions have occur-
red within 24 h of drug infusion (most com-
monly with the first infusion), and it is
therefore recommended that patients be closely
monitored, and treatment be stopped if there is
a severe reaction [30]. Most IRRs occurred dur-
ing the first rituximab infusion (in the first
1–2 h), and the frequency of reactions typically
decreased with subsequent infusions, to less
than 1% after eight doses of rituximab [29, 30].
Now that physicians have more experience of
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rituximab administration, the management of
IRRs has improved, for example, by use of
slower infusion rates and by premedication
(described later), and IRRs now occur less fre-
quently than during the registration trials.
In addition to IRRs, other common AEs
reported in patients treated with rituximab
include infections, hematologic AEs, and car-
diovascular events. Infections (bacterial and
viral) were reported in approximately 30–55%
of patients with NHL and in about 30–50% of
patients with CLL in clinical trials. Grade 3/4
infections occurred in approximately 4% of
patients treated with rituximab as monotherapy
in randomized studies, and were more common
with rituximab maintenance therapy than with
observation [29, 30]. Documented infections in
rituximab-treated patients included localized
Candida infections, herpes zoster, and cytome-
galovirus infections. Rarely, cases of fatal pro-
gressive multifocal leukoencephalopathy and
severe mucocutaneous reactions, some of which
were fatal, have occurred [30]. Hepatitis B reac-
tivation has also been reported, mainly in
patients receiving rituximab plus chemother-
apy, with outcomes of fulminant hepatitis,
hepatic failure, and death in some cases [30].
Among patients with relapsed/refractory CLL,
grade 3/4 hepatitis B (reactivation and primary
infection) was reported in 2% of patients treated
with R-FC compared with 0% of patients treated
with FC [29].
Generally mild and reversible cytopenias,
including neutropenia, leukopenia, and
thrombocytopenia, were reported during treat-
ment with rituximab as monotherapy for
4 weeks in clinical trials, and grade 3/4 events
were relatively uncommon, occurring in 4.2%
(neutropenia), 1.1% (anemia), and 1.7%
(thrombocytopenia) of patients [29]. Compared
with observation, patients treated with ritux-
imab as maintenance therapy for up to 2 years
experienced a higher incidence of grade 3/4
leukopenia (5% vs 2%) and neutropenia (10% vs
4%) but a similar low incidence of thrombocy-
topenia (both less than 1%). In clinical studies
in NHL and CLL, rituximab therapy plus
chemotherapy (CHOP, FC, or CVP) was gener-
ally associated with a higher incidence of grade
3/4 leukopenia, neutropenia, and pancytopenia
compared with chemotherapy alone [29, 30];
however, despite the increased incidence of
neutropenia, patients treated with rituximab
plus chemotherapy were not at higher risk of
developing infections compared with patients
treated with chemotherapy alone [29]. In stud-
ies in previously untreated and relapsed/refrac-
tory CLL, prolonged neutropenia (resolving
between 24 and 42 days after the last dose) or
late-onset neutropenia (resolving later than
42 days after the last dose) was reported more
frequently in those receiving R-FC than in those
receiving FC alone (up to 25% of R-FC patients)
[29, 30].
Cardiovascular events were reported in up to
25% of patients receiving rituximab
monotherapy in clinical trials, most commonly
hypotension and hypertension [29, 30]. Some
cases of grade 3/4 arrhythmias and angina pec-
toris were also reported during infusion of
rituximab. In the maintenance setting, cardiac
disorders were reported as serious AEs in 3% of
rituximab-treated patients and in less than 1%
of untreated patients [29]. In studies evaluating
rituximab in combination with chemotherapy,
R-CHOP was associated with a higher incidence
of grade 3/4 cardiac arrhythmias (mainly
tachycardia and atrial flutter/fibrillation) com-
pared with CHOP [29, 30]; however, there was
no difference between R-CHOP and CHOP in
terms of the incidence of other grade 3/4 cardiac
events, including heart failure, myocardial dis-
ease, and manifestations of coronary artery
disease [29].
Other common AEs reported with rituximab
therapy include respiratory system disorders
(e.g., dyspnea, cough, and chest pain), gas-
trointestinal disorders (e.g., nausea, vomiting,
and diarrhea), skin and suncutaneous tissue
disorders (e.g., pruritus, rash, and urticaria),
metabolic disorders (e.g., angioedema and
hyperglycemia), and nervous system disorders
(e.g., paresthesia, hypoesthesia, and agitation)
[29, 30]. In addition, IgG levels are frequently
reduced among rituximab-treated patients, with
levels below the lower limit of normal reported
in approximately 60% of patients with FL
receiving rituximab maintenance therapy for
2 years (vs 36% in the observation group) [29].
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Safety in Patient Subpopulations
In the current summary of product characteris-
tics for rituximab, brief reference is made to the
tolerability profile of rituximab monotherapy in
specific patient subpopulations with NHL,
including older patients (65 years or older),
patients with bulky disease, and patients
undergoing retreatment [29]. In older patients,
the incidence of ADRs (all grades) and grade 3/4
ADRs is generally similar to that seen in
younger patients (younger than 65 years).
However, in patients with previously untreated
or relapsed/refractory CLL treated with ritux-
imab plus chemotherapy, the incidence and
severity of grade 3/4 hematologic AEs and bac-
terial infections was found to be higher in
patients aged 70 years or older than in younger
patients [30]. In the monotherapy setting,
patients with bulky B-cell lymphomas experi-
enced a higher incidence of grade 3/4 ADRs
than those with nonbulky disease (25.6% vs
15.4%), although the incidence of ADRs of any
grade was generally similar in the two groups
[29]. Retreating patients with further courses of
rituximab monotherapy does not appear to
affect the drug’s tolerability profile, with the
proportion of patients experiencing ADRs dur-
ing later treatment courses being similar to that
during initial exposure (both for grade 3/4 ADRs
and for ADRs of any grade) [29]. Information on
the safety profile of rituximab in children and
adolescents is currently scarce, but a random-
ized phase III trial that is assessing the addition
of rituximab therapy to chemotherapy in this
subpopulation [146] will help to address this
issue.
Management and Prevention Strategies
for Rituximab-Associated Adverse Events
Current rituximab patient information provides
details of management and prevention strate-
gies for rituximab-associated AEs [29, 30]. Before
infusion of rituximab, all patients should
receive premedication, comprising an antihis-
tamine and acetaminophen (paracetamol), to
minimize the occurrence of cytokine-mediated
reactions (flushing, low blood pressure, etc.). In
patients with CLL, adequate hydration and
administration of uricostatics starting 48 h
before infusion of rituximab is recommended to
reduce the risk of tumor lysis syndrome. Pred-
nisone (100 mg intravenously) should also be
administered shortly before rituximab infusion
to decrease the rate and severity of acute infu-
sion reactions and/or cytokine-release syn-
drome; European prescribing information
recommends this for CLL patients with lym-
phocyte counts greater than 25 9 109/L [29].
In the event of mild-to-moderate IRRs, the
infusion rate should be decreased and then
increased on symptom abatement. Some
physicians use a more rapid infusion (90-min
duration) for all infusions after the first dose,
and this dosing option is approved in the USA.
All patients should undergo screening for hep-
atitis B, including assessment of hepatitis B
surface antigen and hepatitis B core antibody
status, before treatment with rituximab because
of the possible risk of reactivation of the disease.
Consideration should also be given to with-
holding antihypertensive medicines 12 h before
rituximab infusion because of the risk of
hypotension.
PHARMACOECONOMIC
CONSIDERATIONS
Numerous pharmacoeconomic analyses of
rituximab have been conducted in the last
20 years that show rituximab is a cost-effective
option compared with reference interventions
for the treatment of B-cell hematologic malig-
nancies, with the incremental cost-effectiveness
ratios consistently at or below national will-
ingness-to-pay thresholds. Table 5 presents a
summary of the key findings from analyses
published between 2010 and 2016, specifically
evaluating the cost-effectiveness of intra-
venously administered rituximab for the treat-
ment of FL [147–154], DLBCL [155–157], and
CLL [158–161]. These studies were performed in
a variety of countries (including several Euro-
pean countries, the USA, Canada, and Australia)
from either a payer perspective or a societal
perspective. Most of the analyses used Markov
models that incorporated outcomes data from
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clinical trials, and a small number were based
on real-life data from large observational
cohorts.
In FL, rituximab was shown to be cost-ef-
fective both as maintenance therapy compared
with observation in the first-line [151, 153] and
relapsed/refractory [147, 149, 152] settings and
as induction therapy combined with
chemotherapy compared with chemotherapy
alone in previously untreated patients
[148, 150]. In DLBCL, rituximab therapy plus
chemotherapy was generally found to be
cost-effective compared with chemotherapy
alone when administered as first-line treatment
[155, 157], although results were conflicting as
to whether cost-effectiveness increased or
decreased with increasing age [155, 157]. In one
analysis based on data from a large observa-
tional cohort of DLBCL patients in the USA,
previously reported cost savings associated with
rituximab-related survival benefits in clinical
trials were not realized; according to the study
authors, this finding was consistent with an
ongoing accrual of medical costs associated
with multiple comorbidities among elderly
cancer survivors treated with rituximab [156].
Cost-effectiveness analyses of rituximab in CLL
evaluated rituximab therapy plus chemother-
apy versus chemotherapy alone in patients with
previously untreated and relapsed/refractory
disease [158–161]. In both settings, rituximab
therapy plus chemotherapy was considered
cost-effective, although in the Ukraine this was
considered applicable only under conditions of
economic stability, cost-effectiveness threshold
growth, or with rituximab price negotiations
[160]. In an analysis that evaluated the eco-
nomic benefit of adding rituximab therapy to
FC chemotherapy in CLL in the USA, R-FC was
found to be cost-effective from both a payer and
a societal perspective [158].
A population analysis of the benefits and
costs of rituximab in patients with FL, DLBCL,
and CLL in the USA over a 15-year period based
on cancer registry data found that almost
280,000 cumulative life years were saved by
combining rituximab therapy with chemother-
apy, corresponding to a net economic gain of
$16.5 billion, when treatment costs were taken
into account [162].
CONCLUSION
Since its first approval 20 years ago, the
anti-CD20 mAb rituximab has changed the
treatment landscape for patients with B-cell
hematologic malignancies and established a
new standard of care. By prolonging survival in
a range of these diseases, rituximab has reduced
mortality and improved the clinical prognosis
for many patients with B-cell malignancies.
Extensive clinical data from the last two decades
have confirmed the efficacy of rituximab and
allowed its tolerability profile to be clearly
defined. On the basis of this evidence, ritux-
imab is now incorporated routinely into treat-
ment regimens for FL, DLBCL, CLL, and MCL: it
is designated as a recommended treatment in
current clinical practice guidelines for B-cell
hematologic malignancies developed by the
European Society of Medical Oncology and the
US National Comprehensive Cancer Network
[9–11, 22, 23], and is included in the WHO
Model List of Essential Medicines [24]. The
experience with rituximab has confirmed the
value of the CD20 protein as an important
mechanistic target in the search for new lym-
phoma treatments. Advances in the design of
anti-CD20 antibodies have resulted in the
development of new therapies for the treatment
of B-cell hematologic malignancies, such as
obinutuzumab, which has shown benefit for the
treatment of FL, both as first-line treatment and
in patients with rituximab-refractory disease,
and CLL (see the reviews by Tobinai et al. [163]
and Goede et al. [164] for detailed assessments
of this agent). Other examples of newer agents
include ofatumumab, veltuzumab, and ocre-
lizumab [165]. Both obinutuzumab and ritux-
imab are important backbones of therapy in this
setting for the foreseeable future. Another
example of development of a drug that exploits
the CD20 pathway is CD20/CD3 antibodies.
Furthermore, the introduction of subcuta-
neously administered rituximab (extensively
reviewed by Davies et al. [31]), with its simpli-
fied administration schedule, reduced treat-
ment burden for patients, and the potential
resource savings for healthcare systems, is likely
to further strengthen the position of rituximab
2264 Adv Ther (2017) 34:2232–2273
as an essential treatment for symptomatic,
advanced B-cell malignancies.
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